Bottom line up front: hormone therapy reduces hot-flash frequency by roughly 75% versus placebo; a JAMA-published trial showed self-administered hypnosis audio cuts hot-flash scores by 53%; cognitive behavioral therapy helps 65–78% of women; and several non-hormonal prescriptions carry Level I evidence. Meanwhile, most supplements, breathing exercises, cooling gadgets, and "menopause diets" have failed controlled testing entirely.
How do we know? The grading below follows The Menopause Society's (formerly NAMS) evidence system: Level I means good, consistent scientific evidence from randomized trials; Level II means limited or inconsistent evidence; Level III means consensus opinion.
Tier 1 — Interventions with the strongest evidence
1. Hormone therapy (HT/MHT): −75% hot-flash frequency
"Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause," states the Society's 2022 position statement. In randomized trials, estrogen therapy — alone or with a progestogen — reduced weekly symptom frequency by 75% (95% CI 64–82%) versus placebo, with no other therapy matching it. It also prevents bone loss and treats genitourinary symptoms.
The benefit–risk calculus is favorable for women under age 60 or within 10 years of menopause onset without contraindications. Risks differ by formulation, dose, route, and timing — which is why individualization with a clinician matters. See our dedicated guide for the full WHI/KEEPS story.
2. Self-administered hypnosis: −53% in a sham-controlled RCT
In a randomized clinical trial published in JAMA Network Open (November 2025), 250 women used self-hypnosis audio files daily for six weeks. Hot-flash scores fell 53.4% versus 40.9% with a sham white-noise control — a significant difference against an active control, which is the hardest test a mind-body therapy can pass. Ninety percent of the hypnosis group rated it beneficial. Clinical hypnosis holds a Level I recommendation.
3. Cognitive behavioral therapy (CBT): 65–78% clinically improved
CBT doesn't necessarily reduce how often flashes occur — it reduces how much they bother and interfere, which drives day-to-day quality of life. Across the MENOS trial programme, 65–78% of women reached clinically significant improvement. Crucially for accessibility, delivery formats with trial support include self-help books and internet-delivered programs, not just therapist-led group sessions. CBT-I (for insomnia) carries the same grade and improved sleep specifically in midlife women.
4. Non-hormonal prescriptions
- SSRIs/SNRIs (Level I) — low-dose paroxetine and venlafaxine-class drugs reduce flash frequency and severity; useful when mood symptoms coexist.
- Gabapentin (Level I) — particularly effective for nighttime hot flashes.
- Fezolinetant (Veozah) (Level I) — a neurokinin-3 antagonist approved in 2023; carries an FDA boxed warning for rare liver injury requiring monitoring.
- Elinzanetant (Lynkuet) — FDA-approved October 2025, first dual NK-1/NK-3 antagonist; phase-3 meta-analysis showed −23 hot-flash episodes per day versus placebo plus improved sleep.
- Oxybutynin (Levels I–II).
Tier 2 — Real evidence, conditional benefit
- Weight loss (Levels II–III): randomized trials of behavioral weight-loss programs show decreased vasomotor symptoms, strongest earlier in the transition.
- Vaginal moisturizers and lubricants: genuine first-line therapy for genitourinary symptoms — upgraded from afterthought when used on a regular schedule.
- Low-dose vaginal estrogen / prasterone / ospemifene: recommended when OTC measures don't relieve genitourinary syndrome of menopause; minimal systemic absorption at vaginal doses.
Not recommended — where trials said no
The 2023 systematic review graded these not recommended:
| Intervention | Grade |
|---|---|
| Supplements & herbal remedies (black cohosh et al.) | Levels I–II |
| Paced respiration as a treatment | Level I |
| Cooling techniques/devices | Level II |
| Avoiding triggers (caffeine/alcohol/spicy food) | Level II |
| Exercise or yoga as a hot-flash treatment | Level II |
| Soy foods/extracts, equol | Level II |
| Mindfulness-based interventions for VMS | Level II |
| Cannabinoids, acupuncture, chiropractic, clonidine | Levels I–III |
| Dietary modification as symptom therapy | Level III |
How placebo confuses everything
Hot-flash trials show placebo improvement rates of 20–66%. This is why sham-controlled designs matter enormously here, why any product claiming ">70% relief!" without sham control should be treated skeptically, and why the hypnosis RCT above — which beat a sham — is such a meaningful result.
Frequently asked questions
What is the most effective treatment for menopause hot flashes?
Does hypnosis really reduce hot flashes?
Do herbal supplements like black cohosh work?
Can CBT help with menopause symptoms?
What non-hormonal prescriptions are available?
References
- The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022.
- The Menopause Society. Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2023 Position Statement. Menopause. 2023.
- Elkins G, et al. Self-Administered Hypnosis vs Sham Hypnosis for Hot Flashes: A Randomized Clinical Trial. JAMA Network Open. 2025;8(11). PMID 41217756.
- Mayo Clinic. Menopause — Diagnosis and treatment. Accessed Aug 2026.
- Pinkerton JV, et al. Consistency of efficacy and safety of elinzanetant across populations: review of the OASIS program. Maturitas. 2026. PMID 42537360.
- FDA approval of elinzanetant (Lynkuet), October 2025; coverage via Patient Care Online.